Objective: HMG CoA Reductase inhibitors, more commonly called statins, are Abstract used in the pharmacological management of hyperlipidaemia. At present, the use of these drugs is increasing worldwide. They have been linked to certain adverse drug reactions, including impotence. The aim of the present study is to explore the basis of the association between statin use and impotence using data from spontaneous reports.
Introduction
system have been used; the terms 'impotence' and 'erectile dysfunction' were also used for retrieving HMG CoA reductase inhibitors, more commonly cases. called statins, have an important role to play in the Exposure information was gathered in Spain pharmacological management of hyperlipidaemias, from the Especialidades Consumo de Medicamentos including hypercholesterolaemias and combined (ECOM) database of the Ministry of Health; this hyperlipidaemia. [1] Accordingly, they are being in-database contains information on community drug creasingly used worldwide. [2] Long-term studies consumption through the Spanish National Health have provided evidence of significant reductions in System, which covers virtually the whole populamorbidity and mortality in patients with ischaemic tion. In France, data were provided by the French disease.
[3] The most common adverse effects of sta-National Health System database corresponding to tins are gastrointestinal disturbances, headache, skin drug sales for outpatients from 1999 to 2002. Drug rashes, dizziness, blurred vision, insomnia, dysgeu-consumption data were converted into defined daily sia, myopathy and increased aminotransferase doses (DDD) [12] and then into treated patients: a levels. [1, 4] consumption of 365 DDD accounted for one patient In addition, statins along with other lipid-lower-treated in a year (DDD used values were those ing drugs, such as fibrates, have also been occasion-proposed by the WHO).
[13] In this manner, the really associated with impotence. [5] [6] [7] [8] [9] The aim of this ported rate can be estimated as the quotient between study is to explore whether there is a rationale upon the number of reported cases and the number of which the association of statin use and impotence person-years.
[14] The estimation of the rate was could be based. The data used in this study originate based on the assumption that the exposed population from spontaneous reports.
was large and the cases were scarce; [15] accordingly, the reporting of suspected adverse reactions associMethods ated with these drugs would follow a Poisson distriInformation from the French (1990 French ( -2004 ) and bution and, based on its relation to the χ 2 distributhe Spanish (1989-2004) pharmacovigilance system tion, confidence limits could be obtained. [16] databases was used; these databases include all the adverse drug reactions gathered from different Results sources from the French and Spanish regional pharmacovigilance centres since 1985 and 1982, In the Spanish database we identified a series of respectively. Briefly, these are decentralised region-38 cases of impotence associated with the use of al centres to which physicians and hospital pharma-statins during the period 1989-2004 (table I) . The cists send spontaneous reports of suspected adverse median age of case patients was 56 years (range drug reactions; events associated with the use of 29-73); with regard to the reaction, the median recently marketed drugs are specifically requested. induction period was 16.5 days (range 0-426) and By definition, cases of overdose are not included in the median recovery period was 27 days (range the databases. Ad hoc committees evaluate all re-6-215). Fifteen patients developed impotence in ports by using an algorithm to establish a causal <15 days after treatment onset and 21 did so after 15 relationship. [10] In both systems, all reports are in-days (the induction period was unknown for two cluded in the database regardless of causality and patients); 16 patients were receiving other drugs at severity. All reactions were coded according to the the same time. There was a temporal sequence of WHO-ART dictionary. [11] events in all cases. Twenty-five of 27 patients in For the purpose of the study, only spontaneous whom the drug was withdrawn improved; 1 of 25 reported cases of impotence associated with statins patients improved after taking the drug on alternate that were collected by the Spanish or French days instead of taking it daily. In three patients in pharmacovigilance systems via the 'yellow card' whom the medication was not withdrawn, the condi- tion continued and there was no further information Our data suggest an association between impoabout the progress in eight patients. In 22 of the tence and the use of statins. Although a causal patients, no other drugs or conditions were reported relationship has not been -and cannot be -estaband in two cases the patients had diabetes mellitus. lished on a case report basis, some of the features of There was one patients with a history of impotence the present series point to such a possibility; the two related to previous use of different statins.
series from the Spanish and French pharmacovigilance systems are consistent. A series of 37 cases were collected in the French database from 1990 to 2004 (table II) . The median In all cases there was a reasonable temporal age of the patients was 52 years (range 36-71). The relationship between the administration of the stamedian induction period was 37.5 days (range tins and the onset of the condition, in most of the 2-2190) and the median recovery period was 16 cases impotence disappeared or improved after stadays (range 2-30). Nine patients developed impo-tin withdrawal, and, finally, in several cases there tence within 15 days after treatment onset and 21 did was a positive rechallenge that permitted conso after 15 days (the induction period was unknown founding by indication to be ruled out. Notwithin 7 patients); 15 patients were also receiving other standing, in a few patients the presences of diabetes drugs and three had diabetes. The reaction improved or some other drugs might have contributed partially in 28 patients after drug withdrawal; in five patients or totally to the condition. the reaction continued after the drug was withdrawn;
No clear characteristics could be identified in in one patient the drug was not withdrawn and the patients developing impotence; spontaneous reports reaction continued; there was no information about are often compounded with incomplete clinical inthe progress in three patients. In five patients a formation. The elapsed time of drug exposure to the positive rechallenge was observed; a previous histodevelopment of impotence ranged from 1 day to ry of impotence was noted in one patient receiving several years, which agrees with other case series nifedipine and fenofibrate and in three patients rereported in the literature. This has probably more to ceiving other statins.
do with the type of the reaction itself and the way The reported incidence rates of impotence for the this is perceived by patients than with the real inducvarious statins are shown in table III and table IV. tion period of the reaction. No clear correlation between reported rates and liData from the literature seem to reinforce this pophilicity was observed. association since two additional case series of 42 and 89 cases of presumably statin-induced impoDiscussion tence have been previously published. [18] [19] [20] [21] In the first one, the Australian Adverse Drug Reactions Impotence is a condition that is not commonly Advisory Committee identified 42 reports of imporeported as an adverse drug reaction; several reasons tence in association with simvastatin; the ages of the could account for this under-reporting: (i) doctors men in the two series ranged from 43 to 72 years usually do not ask about this type of problem; (ii) (median 57 years) and the onset occurred from 48 patients also usually do not complain about such a hours to 27 months (median 6 weeks) since the drug condition to their doctors; and (iii) it is sometimes was first taken. Simvastatin was the only drug implidifficult to attribute the condition to a particular cated in 35 of the reports and there was a positive cause as many factors could account for it. Also, rechallenge in four patients. Out of 29 patients in there is no clear and reliable information on this whom recovery was mentioned, 14 recovered after particular topic for many drugs. This is the case for the drug was discontinued whereas no recovery was statins: no information at all on impotence can be reported for the other 15 at the time. Similarly, in the obtained in this regard for all marketed statins in the UK, the Committee on Safety of Medicines identisummary of the product characteristics, except for fied 89 cases of impotence: 49 associated with atorvastatin. Reporting rate per 1 000 000 male Lipophilicity, C log P (octanol/ patient-years (95% CI) water) [17] 1814 men (2.04%) from the simvastatin group ver-cholesterol; statins are found in small quantities in the testes, where they can inhibit this de novo synsus 28 of 1803 (1.55%) from the placebo group thesis of cholesterol. reported impotence; [23] although the difference was Since reported rates underestimate the real rates not significant because of the sample size (Fisher's of adverse effects, the true risk for this particular exact test, p = 0.32), this difference would account reaction is likely to be higher. Although atorvastatin for an attributable risk for simvastatin of 24.02% in and simvastatin seem to point to a higher rate, no the setting of this randomised clinical trial. significant differences were observed between these Since the pathways for their actions and the strucfigures. tures of the various types of lipid-lowering drugs are different and the result of the use of these drugs is a Conclusion decrease in the cholesterol levels, testosterone synthesis may be affected. [24, 25] This mechanism could In summary, these series further emphasise the explain the association between impotence and all possible association between statins and impotence. types of lipid-lowering drugs since libido is closely Doctors should be aware of this potential adverse related to serum testosterone levels. In addition, in reaction, which could affect a large number of pafamilial hypercholesterolaemia, the low density lip-tients, considering the wide use of this medication oprotein receptor malfunctions, [26] which makes the and the potential under-reporting of this particular Leydig cell more dependent on de novo synthesis of reaction. b Data from the French National Health System corresponding to drug sales for outpatients. WHO DDD value: simvastatin 15mg; pravastatin 20mg; fluvastatin 40mg; atorvastatin 10mg; cerivastatin 0.2mg.
c Logarithm of the partition coefficient based on octanol/water phase. DDDs = defined daily doses.
